Rosuvastatin and progression of atherosclerosis.
Technological advances in arterial wall imaging have provided the opportunity to evaluate the impact of medical therapies on the progression of atherosclerosis in vivo. Arterial imaging has been extensively utilized to determine the impact of high-dose statin therapy. Using multiple imaging modalities in the carotid and coronary territories, rosuvastatin has been demonstrated to have a beneficial impact across the spectrum of cardiovascular risk. The impact of modifying levels of atherogenic lipids, HDL and markers of inflammation will be reviewed.
Nicholls
Stephen J
SJ
Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA. nichols1@ccf.org
D050197:Atherosclerosis / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002339:Carotid Arteries / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology; D018450:Disease Progression; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium